Helicobacter pylori eradication: Equivalence trials and the optimal duration of therapy

American Journal of Gastroenterology

Volumn 100, Issue 8, 2005, Pages 1702-1703

  Vakil, Nimish ^a   Connor, Jason ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b CARNEGIE MELLON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; PROTON PUMP INHIBITOR;

CLINICAL PRACTICE; CLINICAL TRIAL; DRUG DOSE REGIMEN; DYSPEPSIA; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HYPOTHESIS; INTERMETHOD COMPARISON; META ANALYSIS; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT REFUSAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DRUG ADMINISTRATION; DRUG COMBINATION; NOTE;

CONFIDENCE INTERVALS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS;

EID: 25644432070     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.50615.x     Document Type: Review

References (12)

1. Laine L, Estrada R, Trujillo M, et al. Randomized comparison of differing periods of twice a day triple therapy for the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1996;10:1029-33.
2. Yousfi MM, El-Zimaity HMT, Genta RM, et al. One-week therapy with omeprazole, amoxicillin and clarithromycin for treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1996;10:617-21.
3. Vakil N, Lanza F, Schwartz H, et al. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004;20(1):99-107.
4. Connor JT. The value of a P-valueless paper. Am J Gastroenterol 2004;99:1638-40.
5. Blackwelder WC. Proving the null hypothesis in clinical trials. Control Clin Trials 1982;3:345-53.
6. Blackwelder WC. Equivalence trials. Encyclopedia of biostatistics. London: Wiley, 1998.
7. Calvet X, Ducons J, Bujanda L, et al. Seven vs. ten-day of rabeprazole triple therapy for Helicobacter pylori eradication: A multicenter randomized trial. Am J Gastroenterol 2005;100:1696-1701.
8. Broutet N, Tchamgoue S, Pereira E, et al. Risk factors for failure of Helicobacter pylori therapy-Results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003;17(1):99-109.
9. Calvet X, Garcia N, Lopez T, et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14(5):603-9.
10. Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003;17(5):719-26.
11. Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: A prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003;98(3):562-7.
12. Vaira D, Vakil N, Menegatti M, et al. The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann Intern Med 2002;136(4):280-7.